These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
186 related items for PubMed ID: 7936114
21. (-)-Deprenyl inhibits tyramine-induced noradrenaline release, but not tyramine-induced dopamine release or potassium-induced noradrenaline release, from rat brain synaptosomes. Takahata K, Shimazu S, Yoneda F. Pharmacol Res; 2004 Mar; 49(3):253-8. PubMed ID: 14726221 [Abstract] [Full Text] [Related]
22. Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. Fowler JS, Volkow ND, Logan J, Franceschi D, Wang GJ, MacGregor R, Shea C, Garza V, Pappas N, Carter P, Netusil N, Bridge P, Liederman D, Elkashef A, Rotrosen J, Hitzemann R. Life Sci; 2001 May 04; 68(24):2759-68. PubMed ID: 11400918 [Abstract] [Full Text] [Related]
23. L-deprenyl (selegiline) decreases excitatory synaptic transmission in the rat hippocampus via a dopaminergic mechanism. Hsu KS, Huang CC, Su MT, Tsai JJ. J Pharmacol Exp Ther; 1996 Nov 04; 279(2):740-7. PubMed ID: 8930179 [Abstract] [Full Text] [Related]
24. Effect of MAO-B inhibitors on MPP+ toxicity in Vivo. Wu RM, Chen RC, Chiueh CC. Ann N Y Acad Sci; 2000 Nov 04; 899():255-61. PubMed ID: 10863544 [Abstract] [Full Text] [Related]
26. Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW. J Neurochem; 1990 Sep 04; 55(3):981-8. PubMed ID: 2117053 [Abstract] [Full Text] [Related]
27. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine neurons. Engberg G, Elebring T, Nissbrandt H. J Pharmacol Exp Ther; 1991 Nov 04; 259(2):841-7. PubMed ID: 1658311 [Abstract] [Full Text] [Related]
28. The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Braestrup C, Andersen H, Randrup A. Eur J Pharmacol; 1975 Nov 04; 34(1):181-7. PubMed ID: 1241962 [Abstract] [Full Text] [Related]
29. The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145. Fozard JR, Zreika M, Robin M, Palfreyman MG. Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov 04; 331(2-3):186-93. PubMed ID: 3937059 [Abstract] [Full Text] [Related]
30. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. Riederer P, Youdim MB. J Neurochem; 1986 May 04; 46(5):1359-65. PubMed ID: 2420928 [Abstract] [Full Text] [Related]
31. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Olmos G, Gabilondo AM, Miralles A, Escriba PV, García-Sevilla JA. Br J Pharmacol; 1993 Mar 04; 108(3):597-603. PubMed ID: 8385528 [Abstract] [Full Text] [Related]
32. Specific irreversible monoamine oxidase B inhibitors stimulate gene expression of aromatic L-amino acid decarboxylase in PC12 cells. Li XM, Juorio AV, Paterson IA, Zhu MY, Boulton AA. J Neurochem; 1992 Dec 04; 59(6):2324-7. PubMed ID: 1431909 [Abstract] [Full Text] [Related]
33. Behaviour of (-)-deprenyl and its analogues. Magyar K. J Neural Transm Suppl; 1994 Dec 04; 41():167-75. PubMed ID: 7931223 [Abstract] [Full Text] [Related]
34. Different effects of 1-methyl-4-phenyl-pyridinium (MPP+) on monoamine oxidase of dopaminergic terminals in caudate nucleus slices from pigmented and from albino rabbits. Lupp A, Lücking CH, Hedler L, Feuerstein TJ. Naunyn Schmiedebergs Arch Pharmacol; 1993 Feb 04; 347(2):141-6. PubMed ID: 8474535 [Abstract] [Full Text] [Related]
35. Effect of low-dose treatment with selegiline on dopamine transporter (DAT) expression and amphetamine-induced dopamine release in vivo. Lamensdorf I, Porat S, Simantov R, Finberg JP. Br J Pharmacol; 1999 Feb 04; 126(4):997-1002. PubMed ID: 10193780 [Abstract] [Full Text] [Related]
36. [Possible mechanism of selective inhibition of rat liver mitochondrial monoamine oxidase by chlorgiline and deprenyl]. Severina IS. Biokhimiia; 1979 Feb 04; 44(2):195-207. PubMed ID: 435561 [Abstract] [Full Text] [Related]
37. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion. Vaglini F, Pardini C, Cavalletti M, Maggio R, Corsini GU. Brain Res; 1996 Nov 25; 741(1-2):68-74. PubMed ID: 9001706 [Abstract] [Full Text] [Related]
38. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study. Miklya I, Knoll B, Knoll J. Life Sci; 2003 Apr 25; 72(23):2641-8. PubMed ID: 12672509 [Abstract] [Full Text] [Related]
39. Acute effects of moclobemide and deprenyl on 5-HT synthesis rates in the rat brain: An autoradiographic study. Nishi K, Mück-Seler D, Hasegawa S, Watanabe A, Diksic M. Brain Res Bull; 2006 Oct 16; 70(4-6):368-77. PubMed ID: 17027772 [Abstract] [Full Text] [Related]
40. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons. Rothblat DS, Schneider JS. Brain Res; 1998 Jan 01; 779(1-2):226-30. PubMed ID: 9473679 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]